• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

兔体内天然型和碳水化合物修饰型组织纤溶酶原激活剂的清除

Elimination of native and carbohydrate-modified tissue plasminogen activator in rabbits.

作者信息

Einarsson M, Hggroth L, Mattsson C

机构信息

Research Department, Kabi, Stockholm, Sweden.

出版信息

Thromb Haemost. 1989 Dec 29;62(4):1088-93.

PMID:2515604
Abstract

The elimination of native and carbohydrate-modified tissue type plasminogen activator (t-PA) after an i.v. bolus injection was studied in rabbits. t-PA with a low content of mannose (man-t-PA) was obtained by treatment with alpha-mannosidase, which cleaves terminal mannose from the carbohydrate side chains of the molecule. About 50% of the total mannose was removed from the native t-PA. Clearance of t-PA in rabbits was followed by measurements of both the fibrinolytic activity of the activators and the radioactivity of the iodine-labelled compounds. A biphasic mode of elimination of the fibrinolytic activity as well as the radioactivity was found with both the native and the carbohydrate modified t-PA. The initial half-life (t 1/2 alpha) was the same, about 1.5 minutes, for both compounds, irrespective of method of analysis. The late half-life (t 1/2 beta) was also the same, about 15 minutes, for both compounds. However, the beta-elimination of native t-PA could only be determined accurately from radioactivity data in the dosages tested, i.e. up to 2 mg of t-PA. No dose dependency in the elimination pattern was observed. In gel filtration experiments, with plasma from the rabbits, it was demonstrated that in addition to fibrinolytically active t-PA and man-t-PA, both fibrinolytically inactive high molecular weight complexes and low molecular weight degradation products of the activators were present in plasma after injection of the compounds. The second phase of elimination (beta) was much more pronounced after mannosidase treatment of the t-PA.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

通过静脉推注给药后,在兔体内研究了天然型和碳水化合物修饰型组织型纤溶酶原激活剂(t-PA)的消除情况。通过用α-甘露糖苷酶处理获得了低甘露糖含量的t-PA(甘露糖-t-PA),该酶从分子的碳水化合物侧链上切割末端甘露糖。从天然t-PA中去除了约50%的总甘露糖。通过测量激活剂的纤溶活性和碘标记化合物的放射性来跟踪兔体内t-PA的清除情况。天然型和碳水化合物修饰型t-PA的纤溶活性以及放射性的消除均呈现双相模式。两种化合物的初始半衰期(t1/2α)相同,约为1.5分钟,与分析方法无关。两种化合物的晚期半衰期(t1/2β)也相同,约为15分钟。然而,仅在测试剂量(即高达2mg的t-PA)下,才能从放射性数据准确确定天然t-PA的β消除情况。在消除模式中未观察到剂量依赖性。在凝胶过滤实验中,使用兔血浆证明,注射化合物后,血浆中除了具有纤溶活性的t-PA和甘露糖-t-PA外,还存在纤溶无活性的高分子量复合物以及激活剂的低分子量降解产物。t-PA经甘露糖苷酶处理后,消除的第二阶段(β)更为明显。(摘要截短于250字)

相似文献

1
Elimination of native and carbohydrate-modified tissue plasminogen activator in rabbits.兔体内天然型和碳水化合物修饰型组织纤溶酶原激活剂的清除
Thromb Haemost. 1989 Dec 29;62(4):1088-93.
2
Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver.肝脏中甘露糖和半乳糖受体对组织型纤溶酶原激活物的清除作用。
Thromb Haemost. 1990 Feb 19;63(1):60-6.
3
Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).大剂量组织型纤溶酶原激活剂及血浆半衰期延长的杂交纤溶酶原激活剂(K2tu-PA:CGP 42935)的溶栓和出血作用
Thromb Haemost. 1993 Aug 2;70(2):294-300.
4
Total body and hepatic clearance in rats of recombinant tissue-type plasminogen activator expressed in mouse C127 and Chinese hamster ovary cells.在小鼠C127细胞和中国仓鼠卵巢细胞中表达的重组组织型纤溶酶原激活剂在大鼠体内的全身清除率和肝脏清除率。
Drug Metab Dispos. 1992 Jul-Aug;20(4):541-6.
5
Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.人体中内源性组织型纤溶酶原激活剂(t-PA)及其抑制剂的肾脏和肝脏处理过程。
Thromb Haemost. 1988 Jun 16;59(3):404-11.
6
Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation.尽管t-PA在循环中的半衰期较短,但给药后仍有持续的纤维蛋白溶解作用。
Thromb Haemost. 1987 Feb 3;57(1):35-40.
7
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.急性缺血性心脏病患者的纤维蛋白溶解。特别提及组织型纤溶酶原激活剂治疗对纤维蛋白溶解、凝血和补体途径的全身影响。
Dan Med Bull. 1993 Sep;40(4):383-408.
8
Pregnancy zone protein-tissue-type plasminogen activator complexes bind to low-density lipoprotein receptor-related protein (LRP).妊娠区带蛋白-组织型纤溶酶原激活物复合物与低密度脂蛋白受体相关蛋白(LRP)结合。
Arch Biochem Biophys. 2001 May 15;389(2):218-22. doi: 10.1006/abbi.2001.2329.
9
Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
Circulation. 1989 Jun;79(6):1204-13. doi: 10.1161/01.cir.79.6.1204.
10
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(scu-PA)和尿激酶在体外血浆环境中对血凝块溶解不存在协同作用。
Thromb Haemost. 1986 Aug 20;56(1):35-9.

引用本文的文献

1
Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.纤溶酶原激活物抑制剂在正常肝脏、肝硬化肝脏及有转移的肝脏中的分布。
J Clin Pathol. 1994 Mar;47(3):218-21. doi: 10.1136/jcp.47.3.218.
2
Characterization of the binding of plasminogen activators to plasma membranes from human liver.纤溶酶原激活剂与人肝细胞膜结合的特性研究
Biochem J. 1992 Nov 1;287 ( Pt 3)(Pt 3):911-5. doi: 10.1042/bj2870911.
3
Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
在大肠杆菌中产生的未糖基化重组组织型纤溶酶原激活剂(BM 06.021)的药代动力学和溶栓特性。
Naunyn Schmiedebergs Arch Pharmacol. 1992 Jul;346(1):108-13. doi: 10.1007/BF00167579.